Literature DB >> 24872110

Classification of endometrial carcinoma: more than two types.

Rajmohan Murali1, Robert A Soslow2, Britta Weigelt3.   

Abstract

Endometrial cancer is the most common gynaecological malignancy in Europe and North America. Traditional classification of endometrial carcinoma is based either on clinical and endocrine features (eg, types I and II) or on histopathological characteristics (eg, endometrioid, serous, or clear-cell adenocarcinoma). Subtypes defined by the different classification systems correlate to some extent, but there is substantial heterogeneity in biological, pathological, and molecular features within tumour types from both classification systems. In this Review we provide an overview of traditional and newer genomic classifications of endometrial cancer. We discuss how a classification system that incorporates genomic and histopathological features to define biologically and clinically relevant subsets of the disease would be useful. Such integrated classification might facilitate development of treatments tailored to specific disease subgroups and could potentially enable delivery of precision medicine to patients with endometrial cancer.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24872110     DOI: 10.1016/S1470-2045(13)70591-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  167 in total

1.  Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.

Authors:  Yaser R Hussein; Britta Weigelt; Douglas A Levine; J Kenneth Schoolmeester; Linda N Dao; Bonnie L Balzer; Georgia Liles; Beth Karlan; Martin Köbel; Cheng-Han Lee; Robert A Soslow
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

Review 2.  Pathophysiology of heavy menstrual bleeding.

Authors:  Dharani K Hapangama; Judith N Bulmer
Journal:  Womens Health (Lond)       Date:  2015-12-23

3.  The genetic landscape of endometrial clear cell carcinomas.

Authors:  Deborah F DeLair; Kathleen A Burke; Pier Selenica; Raymond S Lim; Sasinya N Scott; Sumit Middha; Abhinita S Mohanty; Donavan T Cheng; Michael F Berger; Robert A Soslow; Britta Weigelt
Journal:  J Pathol       Date:  2017-09-05       Impact factor: 7.996

4.  Increased frequency of regulatory T cells in the peripheral blood of patients with endometrioid adenocarcinoma.

Authors:  Li Li; Yinghua Li; Zhuomin Yin; Jing Zhu; Dingding Yan; Hanmei Lou
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

5.  miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas.

Authors:  Ying Dong; Jing-Wen Si; Wen-Ting Li; Li Liang; Jian Zhao; Mei Zhou; Dong Li; Ting Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

6.  Endometrial Cancer Trends by Race and Histology in the USA: Projecting the Number of New Cases from 2015 to 2040.

Authors:  Charles Gaber; Rafael Meza; Julie J Ruterbusch; Michele L Cote
Journal:  J Racial Ethn Health Disparities       Date:  2016-10-17

Review 7.  Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?

Authors:  S Marnitz; C Köhler; N Gharbi; S Kunze; K Jablonska; J Herter
Journal:  Strahlenther Onkol       Date:  2018-08-15       Impact factor: 3.621

8.  Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.

Authors:  Aliyah Almomen; Elke A Jarboe; Mark K Dodson; C Matthew Peterson; Shawn C Owen; Margit M Janát-Amsbury
Journal:  Pharm Res       Date:  2016-05-31       Impact factor: 4.200

9.  Metabolic syndrome and risk of endometrial cancer in the united states: a study in the SEER-medicare linked database.

Authors:  Britton Trabert; Nicolas Wentzensen; Ashley S Felix; Hannah P Yang; Mark E Sherman; Louise A Brinton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-01       Impact factor: 4.254

Review 10.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.